Back
ESC2025 Premium Access

THRV-1268, a novel and potent SGK1 inhibitor, improved adverse cardiac remodeling beyond empagliflozin, an SGLT2 inhibitor, by reducing inflammation and fibrosis mechanisms in heart failure.

Session: SGLT2 inhibitors in heart failure: prevention and treatment
Topic: Heart Failure with Reduced Ejection Fraction (HFrEF)
Speaker: Doctor S. Das (Boston, US)
Event: ESC Congress 2025

Congress Presentation

Add to my library

Like

About the speaker

Doctor Saumya Das

Massachusetts General Hospital - Harvard Medical School, Boston (United States of America)
1 presentation
0 follower

3 more presentations in this session

Right vs. left cardiac function and structure: impact of SGLT2i in acute decompensate heart failure with central sleep apnea

Speaker: Assistant Professor P. Kalaydzhiev (Sofia, BG)

Access
Abstract
Slides
Video
Like
Thumbnail

Two years follow-up of use of SGLT2 inhibitors in HFrEF patients hospitalized for decompensation

Speaker: Associate Professor V. Vintila (Bucharest, RO)

Access
Abstract
Slides
Video
Like
Thumbnail

SGLT2 inhibitors improve cardiovascular clinical outcomes in patients undergoing anthracycline chemotherapy: a systematic review and meta-analysis of 13,333 patients.

Speaker: Doctor L. Spadafora (Latina, IT)

Access
Abstract
Slides
Video
Like
Thumbnail

Access the full session

SGLT2 inhibitors in heart failure: prevention and treatment

Speakers: Doctor S. Das, Assistant Professor P. Kalaydzhiev, Associate Professor V. Vintila, Doctor L. Spadafora
Access
Like
Thumbnail

About the event

Image

ESC Congress 2025

29 August - 1 September 2025

Sessions Presentations

Congress
logo Image

ESC 365 is supported by

bristol-myers-squibb Explore sponsored resources
novartis Explore sponsored resources
novo-nordisk Explore sponsored resources